Dutch Universities and Hospitals Team Up to Build a Robot That Makes Ultra-Precise Surgery Available to More Patients
Eindhoven, Monday, 8 June 2026.
A new surgical robot, developed since 2016 by TU/e, Maastricht UMC+, and spinout Microsure, filters hand tremors and scales movements to superhuman precision — potentially opening complex microsurgery to far more patients worldwide.
A Decade in the Making
This is a healthtech story — one that sits at the intersection of surgical robotics, medical engineering, and patient access. The collaboration between Eindhoven University of Technology (TU/e) and Maastricht University Medical Centre+ (MUMC+) formally gave rise to Microsure in 2016, making the journey to this point a full decade in development [1]. Microsure is a TU/e spin-off company, born out of the university’s Knowledge Transfer Office, which supports hundreds of spin-off companies annually, holds shares in approximately 70 such ventures, and reinvests revenues into scientific research through the TU/e Innovation Fund [1]. The robot at the center of this announcement is the MUSA — a surgical robotic system designed specifically for open microsurgery, the kind of painstaking, high-magnification work that cannot be performed laparoscopically [5].
What Microsurgery Is — and Why It Is So Hard
Microsurgery involves operating on extremely small anatomical structures — blood vessels, lymphatic channels, and nerves — that are often no wider than a few millimetres [GPT]. The procedures demand a level of hand steadiness and spatial accuracy that pushes the limits of human physiology. Even the most experienced surgeons contend with involuntary hand tremors, and the margin for error in connecting tiny vessels or restoring nerve pathways is extraordinarily slim [GPT]. This is precisely what makes the field so exclusive: it is concentrated in a small number of academic hospitals and performed by a very limited pool of highly trained specialists [1]. The consequence for patients is significant — access to microsurgical treatment can depend heavily on geography, hospital resources, and the availability of a qualified surgeon.
How the MUSA Robot Works — and Who Leads It
The MUSA robot addresses the core physical limitations of human surgeons by filtering out hand tremors and scaling down movements, allowing the robotic instruments to execute actions with a precision that exceeds what the unassisted human hand can achieve [1]. By lowering the skill barrier associated with these procedures, the system is designed to make it possible for a broader range of surgeons — not just elite specialists — to perform complex microsurgical interventions [1]. Leading the company that built it is Iwan van Vijfeijken, CEO of Microsure, a four-time medtech entrepreneur who previously worked at NXP Semiconductors before transitioning into medical technology [5]. Van Vijfeijken has navigated multiple ventures, including Pulsify Medical, a cardiac monitoring startup that raised €10 million before going bankrupt, before taking the helm at Microsure [5]. To date, the MUSA robot has been used in over 900 clinical cases across 13 European centers [5]. On the clinical side, the project is co-founded by Tom van Mulken, a plastic surgeon at MUMC+ who has emphasized that the collaboration between surgical expertise and engineering capability was indispensable: “Without the cross-pollination between different disciplines, we would not have been able to develop this surgical robot” [1].
Clinical Trials and the Procedures on the Table
A formal clinical study is currently underway at MUMC+ to evaluate the robot’s performance in a range of complex reconstructive microsurgical procedures [1]. The procedures under evaluation include breast reconstruction, lymphedema treatment, trauma or cancer reconstructions, and nerve restoration [1]. The study is designed to determine whether robotic assistance can reduce operating times, lower the rate of complications, and shorten hospital stays — outcomes that would carry significant implications for both patients and healthcare systems [1]. Tom van Mulken has stated directly: “The collaboration between surgeon and technology ensures greater stability and precision during a procedure. This, in turn, increases the likelihood of better outcomes and faster recovery for the patient” [1]. The clinical findings from MUMC+ will be critical in establishing the evidence base needed for broader deployment of the technology across more hospitals and healthcare systems.
From Eindhoven to Vienna: Building Momentum in European Surgical Robotics
The momentum behind Microsure is increasingly visible on the European medical stage. As recently as 28–30 May 2026 — just days before this announcement on 8 June 2026 — Microsure participated as a sponsor and exhibitor at the 36th Annual Meeting of the European Association of Plastic Surgeons (EURAPS 2026), held at the Austria Trend Hotel Savoyen in Vienna, Austria [4]. The gathering brought together leading clinicians, researchers, and innovators in plastic and reconstructive surgery from across Europe and beyond [4]. Meanwhile, the MUSA system’s reach is not limited to the Netherlands. As of early 2026, Rush University Medical Center in Chicago had acquired a Symani Surgical System [alert! ‘The Chicago Business source references the Symani Surgical System at Rush University Medical Center, but does not explicitly confirm this is the MUSA robot or a Microsure product — these may be separate robotic microsurgery platforms’] and Dr. John O’Toole, chair of the department of neurological surgery at Rush, was among the first surgeons to test the system [2]. The broader pattern is clear: robotic microsurgery is transitioning from a niche research curiosity into a clinically validated discipline with growing institutional adoption on both sides of the Atlantic.
What This Means for Patients and the Healthcare System
The practical implications of a successful robotic microsurgery program extend well beyond the operating theater. If the ongoing clinical study at MUMC+ confirms that the MUSA robot reduces operating times and complications, the pressure on specialist surgeons could be meaningfully relieved — enabling the same volume of procedures to be performed by a larger pool of trained clinicians [1]. Conditions such as lymphedema, which affects millions of people globally following cancer treatment [GPT], and complex nerve damage often go undertreated not because solutions do not exist, but because the surgical expertise required is scarce. TU/e’s broader innovation ecosystem supports this kind of translational development: the university’s Knowledge Transfer Office not only assists entrepreneurial scientists in securing intellectual property rights but also provides training, coaching, and educational programs to bring research from the lab into the clinic [1]. The Microsure story is, in many respects, a model of how a university, a hospital, and a dedicated startup can combine to produce technology with genuine population-level health impact — built over ten years, refined through hundreds of clinical cases, and now poised for wider deployment.